Fifth Third Bancorp
CTKB icon

Fifth Third Bancorp’s Cytek Biosciences CTKB Stock Holding History

Fifth Third Bancorp’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.43K Sell
1,452
-23,457
-94% -$100K ﹤0.01% 3859
2026
Q1 		$109K Buy
24,909
+23,997
+2,631% +$113K ﹤0.01% 2872
2025
Q4 		$4.61K Buy
912
+52
+6% +$241 ﹤0.01% 2313
2025
Q3 		$2.98K Sell
860
-836
-49% -$3.14K ﹤0.01% 2416
2025
Q2 		$5.77K Buy
1,696
+859
+103% +$2.86K ﹤0.01% 2163
2025
Q1 		$3.36K Sell
837
-1,283
-61% -$6.65K ﹤0.01% 2270
2024
Q4 		$13.8K Sell
2,120
-56
-3% -$334 ﹤0.01% 1888
2024
Q3 		$12.1K Buy
2,176
+1,350
+163% +$7.66K ﹤0.01% 1935
2024
Q2 		$4.61K Buy
826
+70
+9% +$420 ﹤0.01% 2139
2024
Q1 		$5.07K Hold
756
– – ﹤0.01% 2053
2023
Q4 		$6.89K Buy
756
+627
+486% +$3.95K ﹤0.01% 2083
2023
Q3 		$712 Sell
129
-430
-77% -$3.45K ﹤0.01% 2484
2023
Q2 		$4.77K Buy
+559
New +$5.01K ﹤0.01% 2211

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fifth Third Bancorp's CTKB Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Cytek Biosciences (CTKB) stake by 94% in Q2 2026, selling an estimated $100K and leaving 1,452 shares worth $6.43K. The position accounts for ﹤0.01% of the portfolio, ranked #3859.

Fifth Third Bancorp first reported a position in CTKB in Q2 2023 and has held it in 13 quarters since. The position peaked at $109K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Fifth Third Bancorp held 1,452 shares of Cytek Biosciences worth $6.43K as of Q2 2026.
  • Fifth Third Bancorp sold 23,457 Cytek Biosciences shares in Q2 2026, an estimated $100K.
  • Cytek Biosciences made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3859 holding.
  • Fifth Third Bancorp first reported a position in Cytek Biosciences in Q2 2023 and has held it in 13 quarters since.
  • Fifth Third Bancorp's Cytek Biosciences position peaked at $109K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.